Novavax Inc. Watch

from 10-Q 79 pages Certain Information Identified With [***] Has Been Excluded From This Exhibit Because It Is Both (I) Not Material and (II) Is the Type That the Registrant Treats as Private or Confidential. Collaboration and Exclusive License Agreement, as Amended

from 10-Q 6 pages Consulting Agreement

from 10-Q 6 pages General Release of Claims and Separation Agreement

from 10-K 3 pages Dear Novavax, Letter of Amendment to the Termination and Settlement Agreement Dated 1 November 2024

from 10-K 25 pages Certain Information Identified With [***] Has Been Excluded From This Exhibit Because It Is Both (I) Not Material and (II) Is of the Type That the Registrant Treats as Private or Confidential

from 10-K 16 pages Amendment #5

from 10-Q 43 pages Certain Information Identified With [***] Has Been Excluded From This Exhibit Because It Is Both (I) Not Material and (II) Is the Type That the Registrant Treats as Private or Confidential. Supply Agreement Between Novavax Inc and Serum Life Sciences Limited

from 10-Q 9 pages Consulting Agreement This Consulting Agreement (This “Agreement”) Is Entered Into as of May 29, 2024 by and Between Novavax, Inc. (“Novavax”), a Corporation Having Its Principal Office at 700 Quince Orchard Road, Gaithersburg, MD 20878 (“Novavax” or the “Company”) and Filip Dubovsky (“Executive”). Whereas, Executive Has Resigned and Intends to Retire From His Employment With the Company as Its President, Research & Development Effective as of June 30, 2024 (The “Effective Date”); Whereas, Executive Has Agreed to Provide Consulting Services and Act as Advisor to the Company Following His Retirement and Beginning on the Effective Date; and Whereas, the Company and Executive Desire to Enter Into This Agreement Setting Forth the Terms of Executive’s Consulting and Advisory Relationship With the Company and Certain Other Matters Relating to the Transition to a Consultant. Now Therefore, in Consideration of the Premises and the Mutual Covenant and Agreements Herein Contained, the Parties Hereto Agree as Follows

from 10-Q 163 pages Certain Information Identified With [***] Has Been Excluded From This Exhibit Because It Is Both (I) Not Material and (II) Is of the Type That the Registrant Treats as Private or Confidential. Collaboration and License Agreement Between Sanofi Pasteur Inc. and Novavax, Inc. Effective Date: May 10, 2024

from 8-K 17 pages Securities Subscription Agreement

from 10-Q 30 pages Certain Information Identified With [***] Has Been Excluded From This Exhibit Because It Is Both (I) Not Material and (II) Is of the Type That the Registrant Treats as Private or Confidential

from 10-Q 31 pages Certain Information Identified With [***] Has Been Excluded From This Exhibit Because It Is Both (I) Not Material and (II) Is of the Type That the Registrant Treats as Private or Confidential

from 10-Q 31 pages Certain Information Identified With [***] Has Been Excluded From This Exhibit Because It Is Both (I) Not Material and (II) Is of the Type That the Registrant Treats as Private or Confidential

from 10-Q 8 pages Certain Information Identified With [***] Has Been Excluded From This Exhibit Because It Is Both (I) Not Material and (II) Is of the Type That the Registrant Treats as Private or Confidential. Confidential Settlement Agreement and Release

from 10-K 42 pages Termination and Settlement Agreement

from 10-K 7 pages Employment Agreement

from 10-K 2 pages Material contract

from 10-K 8 pages Employment Agreement

from 10-K 2 pages Material contract

from 10-K 8 pages Employment Agreement